Investors with a lot of money to spend have taken a bullish stance on Pfizer PFE.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 9 uncommon options trades for Pfizer.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 44%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $756,145, and 5 are calls, for a total amount of $390,670.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $30.0 for Pfizer over the last 3 months.
Insights into Volume & Open Interest
In today's trading context, the average open interest for options of Pfizer stands at 8175.14, with a total volume reaching 29,242.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Pfizer, situated within the strike price corridor from $15.0 to $30.0, throughout the last 30 days.
Pfizer 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | PUT | TRADE | BULLISH | 02/07/25 | $0.29 | $0.23 | $0.24 | $24.00 | $518.4K | 12 | 20 |
| PFE | CALL | SWEEP | BEARISH | 01/24/25 | $11.5 | $11.45 | $11.4 | $15.00 | $148.2K | 17 | 130 |
| PFE | CALL | SWEEP | BEARISH | 01/17/25 | $1.61 | $1.58 | $1.59 | $25.00 | $136.8K | 37.6K | 972 |
| PFE | PUT | SWEEP | BULLISH | 02/07/25 | $0.46 | $0.25 | $0.25 | $24.00 | $125.0K | 12 | 26.6K |
| PFE | PUT | TRADE | BULLISH | 05/16/25 | $4.5 | $4.45 | $4.45 | $30.00 | $62.7K | 559 | 151 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Pfizer's Current Market Status
- Currently trading with a volume of 10,754,819, the PFE's price is down by -0.85%, now at $26.39.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 36 days.
Professional Analyst Ratings for Pfizer
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $31.333333333333332.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Guggenheim persists with their Buy rating on Pfizer, maintaining a target price of $33. * Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Pfizer with a target price of $32. * In a cautious move, an analyst from B of A Securities downgraded its rating to Neutral, setting a price target of $29.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
